User menu

Soluble ST2 plasma concentrations predict mortality in severe sepsis

Bibliographic reference Hoogerwerf, Jacobien J. ; Wittebole, Xavier ; Laterre, Pierre-François ; Tanck, Michael W. T. ; van Zoelen, Marieke A. D. ; et. al. Soluble ST2 plasma concentrations predict mortality in severe sepsis. In: Intensive Care Medicine, Vol. 36, no. 4, p. 630-7 (2010)
Permanent URL
  1. Angus DC, Wax RS (2001) Epidemiology of sepsis: an update. Crit Care Med 29:S109–S116
  2. Hotchkiss RS, Karl IE (2003) The pathophysiology and treatment of sepsis. N Engl J Med 348:138–150
  3. Hotchkiss RS, Nicholson DW (2006) Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 6:813–822
  4. van der Poll T, Opal SM (2008) Host–pathogen interactions in sepsis. Lancet Infect Dis 8:32–43
  5. Volk HD, Reinke P, Docke WD (2000) Clinical aspects: from systemic inflammation to ‘immunoparalysis’. Chem Immunol 74:162–177
  6. Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124:783–801
  7. Beutler B, Jiang Z, Georgel P, Crozat K, Croker B, Rutschmann S, Du X, Hoebe K (2006) Genetic analysis of host resistance: toll-like receptor signaling and immunity at large. Annu Rev Immunol 24:353–389
  8. Liew FY, Xu D, Brint EK, O’Neill LA (2005) Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 5:446–458
  9. Deng JC, Cheng G, Newstead MW, Zeng X, Kobayashi K, Flavell RA, Standiford TJ (2006) Sepsis-induced suppression of lung innate immunity is mediated by IRAK-M. J Clin Invest 116:2532–2542
  10. Brint EK, Xu D, Liu H, Dunne A, McKenzie AN, O’Neill LA, Liew FY (2004) ST2 is an inhibitor of interleukin 1 receptor and toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol 5:373–379
  11. Xu D, Chan WL, Leung BP, Huang F, Wheeler R, Piedrafita D, Robinson JH, Liew FY (1998) Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med 187:787–794
  12. Moritz DR, Rodewald HR, Gheyselinck J, Klemenz R (1998) The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells and on fetal blood mast cell progenitors. J Immunol 161:4866–4874
  13. Oshikawa K, Yanagisawa K, Tominaga S, Sugiyama Y (2002) ST2 protein induced by inflammatory stimuli can modulate acute lung inflammation. Biochem Biophys Res Commun 299:18–24
  14. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23:479–490
  15. Bergers G, Reikerstorfer A, Braselmann S, Graninger P, Busslinger M (1994) Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J 13:1176–1188
  16. Hayakawa H, Hayakawa M, Kume A, Tominaga S (2007) Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 282:26369–26380
  17. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT (2007) IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 117:1538–1549
  18. OSHIKAWA KATSUHISA, KUROIWA KENJI, TAGO KENJI, IWAHANA HIROYUKI, YANAGISAWA KEN, OHNO SHOJI, TOMINAGA SHIN-ICHI, SUGIYAMA YUKIHIKO, Elevated Soluble ST2 Protein Levels in Sera of Patients with Asthma with an Acute Exacerbation, 10.1164/ajrccm.164.2.2008120
  19. Tajima S, Oshikawa K, Tominaga S, Sugiyama Y (2003) The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest 124:1206–1214
  20. Kuroiwa K, Arai T, Okazaki H, Minota S, Tominaga S (2001) Identification of human ST2 protein in the sera of patients with autoimmune diseases. Biochem Biophys Res Commun 284:1104–1108
  21. Brunner Markus, Krenn Claus, Roth Georg, Moser Bernhard, Dworschak Martin, Jensen-Jarolim Erika, Spittler Andreas, Sautner Thomas, Bonaros Nico, Wolner Ernst, Boltz-Nitulescu George, Ankersmit HendrikJan, Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma, 10.1007/s00134-004-2184-x
  22. Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, Rouleau JL, Lee RT (2002) Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 106:2961–2966
  23. Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, Lee RT (2004) Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 109:2186–2190
  24. Yin H, Huang BJ, Yang H, Huang YF, Xiong P, Zheng F, Chen XP, Chen YF, Gong FL (2006) Pretreatment with soluble ST2 reduces warm hepatic ischemia/reperfusion injury. Biochem Biophys Res Commun 351:940–946
  25. Fagundes CT, Amaral FA, Souza AL, Vieira AT, Xu D, Liew FY, Souza DG, Teixeira MM (2007) ST2, an IL-1R family member, attenuates inflammation and lethality after intestinal ischemia and reperfusion. J Leukoc Biol 81:492–499
  26. Lohning M, Stroehmann A, Coyle AJ, Grogan JL, Lin S, Gutierrez-Ramos JC, Levinson D, Radbruch A, Kamradt T (1998) T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci USA 95:6930–6935
  27. Oshikawa K, Yanagisawa K, Tominaga S, Sugiyama Y (2002) Expression and function of the ST2 gene in a murine model of allergic airway inflammation. Clin Exp Allergy 32:1520–1526
  28. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 31:1250–1256
  29. Dellinger RP, Carlet JM, Gerlach H, Ramsey G, Levy M (2004) The surviving sepsis guidelines: not another “groundhog day”. Crit Care Med 32:1601–1602
  30. van Zoelen MA, Laterre PF, van Veen SQ, van Till JW, Wittebole X, Bresser P, Tanck MW, Dugernier T, Ishizaka A, Boermeester MA, van der Poll T (2007) Systemic and local high mobility group box 1 concentrations during severe infection. Crit Care Med 35:2799–2804
  31. (1992) American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864–874
  32. Becerra A, Warke RV, de Bosch N, Rothman AL, Bosch I (2008) Elevated levels of soluble ST2 protein in dengue virus infected patients. Cytokine 41:114–120
  33. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT (2003) Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 107:721–726
  34. Calandra T, Gerain J, Heumann D, Baumgartner JD, Glauser MP (1991) High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss–Dutch J5 immunoglobulin study group. Am J Med 91:23–29
  35. Casey Larry C., Plasma Cytokine and Endotoxin Levels Correlate with Survival in Patients with the Sepsis Syndrome, 10.7326/0003-4819-119-8-199310150-00001
  36. Damas P, Reuter A, Gysen P, Demonty J, Lamy M, Franchimont P (1989) Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 17:975–978
  37. Marks James D., Marks Cara Berman, Ljuce John M., Montgomery A. Bruce, Turner Joan, Metz Craig A., Murray John F., Plasma Tumor Necrosis Factor in Patients with Septic Shock: Mortality Rate, Incidence of Adult Respiratory Distress Syndrome, and Effects of Methylprednisolone Administration, 10.1164/ajrccm/141.1.94
  38. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E (1993) Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 103:565–575
  39. Hack CE, Aarden LA, Thijs LG (1997) Role of cytokines in sepsis. Adv Immunol 66:101–195